Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
68Ga-SATO
- Development stage
- Phase 2
- Lead developer
- Princess Máxima Center for Pediatric Oncology
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
68Ga-SATO is a radiopharmaceutical diagnostic agent developed by the Princess Máxima Center for Pediatric Oncology for the positron emission tomography (PET) imaging of neuroblastoma. It consists of a small-molecule ligand, SATO-1, which is labeled with the positron-emitting radioisotope Gallium-68 (68Ga). The tracer specifically targets the Tropomyosin receptor kinase B (TrkB), also known as NTRK2, a tyrosine kinase receptor that is frequently overexpressed in high-risk neuroblastoma and is associated with aggressive tumor behavior, poor prognosis, and resistance to standard therapies. By binding to TrkB with high affinity, 68Ga-SATO allows for the non-invasive visualization and quantification of TrkB expression in vivo. This imaging tool is intended to improve tumor detection, facilitate accurate staging, and assist in the selection of patients who may benefit from Trk-targeted therapies.
- Other names
- Gallium-68 SATOGallium68 SATOGallium 68 SATO[68Ga]Ga-SATO-1
Beyond the preview
Go deeper on 68Ga-SATO.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 68Ga-SATO.